Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chronic Kidney Disease I: Introduction01:25

Chronic Kidney Disease I: Introduction

565
Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...
565
Antihypertensive Drugs: Potassium-Sparing Diuretics01:28

Antihypertensive Drugs: Potassium-Sparing Diuretics

2.2K
Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
2.2K
Chronic Kidney Disease IV: Nursing Management01:18

Chronic Kidney Disease IV: Nursing Management

321
Nursing management is essential for preventing complications, maintaining stability, and improving patients' quality of life in chronic kidney disease (CKD). By using a structured approach, nurses help slow CKD progression and support effective patient care​.1. Comprehensive patient assessmentEffective management begins with nurses reviewing the patient’s medical history, and identifying key risk factors like diabetes, hypertension, and nephrotoxic drug use. Nurses assess signs of...
321
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

344
Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
344
Introduction to Urinary System01:13

Introduction to Urinary System

8.5K
The urinary system consists of two kidneys, two ureters, the urinary bladder, and the urethra.
The kidneys are bean-shaped organs located in the retroperitoneal space, on either side of the vertebral column, between the T12 and L3 vertebrae. They are partially protected by the rib cage and surrounded by perirenal fat, which provides cushioning. They are responsible for urine formation and play critical roles in regulating blood pressure, electrolyte levels, and hormone production. The ureters...
8.5K
Hormonal Regulation01:33

Hormonal Regulation

35.7K
The renin-aldosterone system is an endocrine system which guides the renal absorption of water and electrolytes, thus managing blood pressure and osmoregulation. Activation of the system begins in the kidneys with a small cluster of cells adjacent to the afferent and efferent blood vessels of the renal corpuscle. As the nephrons are filtering blood, juxtaglomerular cells monitor blood pressure. If they detect a decrease in pressure, they release the hormone renin into the bloodstream.
35.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Iodine in Health and Disease: A Comprehensive Review.

Nutrients·2026
Same author

Primary Aldosteronism and Cognitive Dysfunction: A Case-Control Study.

Journal of clinical medicine·2025
Same author

Cost-benefit analysis of the National Immunization Program in Spain.

Human vaccines & immunotherapeutics·2024
Same author

Rescue treatment of severe lupus myocarditis and proliferative lupus nephritis with immunoadsorption.

Clinical rheumatology·2023
Same author

Costs of the management of hemophilia A with inhibitors in Spain.

Global & regional health technology assessment·2023
Same author

Production of Marine Probiotic Bacteria in a Cost-Effective Marine Media Based on Peptones Obtained from Discarded Fish By-Products.

Microorganisms·2020

Related Experiment Video

Updated: Jan 16, 2026

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats
05:34

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats

Published on: April 4, 2025

1.5K

Aldosterone in Chronic Kidney Disease.

Paula Polenus1, Ana Đuran2, Sandra Karanović Štambuk1,3

  • 1School of Medicine, University of Zagreb, 10000 Zagreb, Croatia.

Biomedicines
|September 27, 2025
PubMed
Summary

Mineralocorticoid receptor overactivation drives chronic kidney disease progression. Novel therapies targeting aldosterone, like finerenone, show promise in reducing residual risk and improving patient outcomes.

Keywords:
aldosteronealdosterone synthase inhibitorschronic kidney diseasemineralocorticoid receptorsnon-steroidal mineralocorticoid receptor antagonists

More Related Videos

5/6th Nephrectomy in Combination with High Salt Diet and Nitric Oxide Synthase Inhibition to Induce Chronic Kidney Disease in the Lewis Rat
08:50

5/6th Nephrectomy in Combination with High Salt Diet and Nitric Oxide Synthase Inhibition to Induce Chronic Kidney Disease in the Lewis Rat

Published on: July 3, 2013

24.3K
Comparative Proteomic Analysis of Whole Kidney, Medulla, and Cortical Tubules in Diabetic Pathogenesis of Kidney Injury in Mice
10:31

Comparative Proteomic Analysis of Whole Kidney, Medulla, and Cortical Tubules in Diabetic Pathogenesis of Kidney Injury in Mice

Published on: May 2, 2025

615

Related Experiment Videos

Last Updated: Jan 16, 2026

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats
05:34

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats

Published on: April 4, 2025

1.5K
5/6th Nephrectomy in Combination with High Salt Diet and Nitric Oxide Synthase Inhibition to Induce Chronic Kidney Disease in the Lewis Rat
08:50

5/6th Nephrectomy in Combination with High Salt Diet and Nitric Oxide Synthase Inhibition to Induce Chronic Kidney Disease in the Lewis Rat

Published on: July 3, 2013

24.3K
Comparative Proteomic Analysis of Whole Kidney, Medulla, and Cortical Tubules in Diabetic Pathogenesis of Kidney Injury in Mice
10:31

Comparative Proteomic Analysis of Whole Kidney, Medulla, and Cortical Tubules in Diabetic Pathogenesis of Kidney Injury in Mice

Published on: May 2, 2025

615

Area of Science:

  • Nephrology
  • Cardiology
  • Endocrinology

Background:

  • Chronic kidney disease (CKD) poses a global health burden with significant morbidity and mortality.
  • Existing treatments like RAS inhibitors and SGLT2 inhibitors leave a substantial residual risk.
  • Aldosterone overactivation is a key factor in CKD progression, causing renal inflammation and fibrosis.

Purpose of the Study:

  • To review the pathophysiology of aldosterone in CKD.
  • To explore emerging therapeutic strategies targeting the mineralocorticoid receptor pathway.
  • To address the unmet need in managing residual risk in CKD patients.

Main Methods:

  • Review of physiological regulation of aldosterone synthesis and secretion.
  • Analysis of aldosterone breakthrough under RAS blockade.
  • Evaluation of mechanisms of aldosterone-mediated kidney damage.
  • Assessment of novel therapeutic agents, including non-steroidal MRAs and aldosterone synthase inhibitors.

Main Results:

  • Finerenone, a novel non-steroidal MRA, demonstrates improved safety and efficacy in reducing renal and cardiovascular outcomes.
  • Aldosterone synthase inhibitors offer an upstream approach to decrease aldosterone production.
  • These agents show potential in mitigating residual cardiovascular and renal risks in CKD.

Conclusions:

  • Targeting aldosterone overactivation is crucial for managing CKD progression.
  • Novel therapeutics like finerenone and aldosterone synthase inhibitors represent promising strategies.
  • These advancements may significantly improve long-term outcomes for CKD patients by reducing residual risk.